FilingReader Intelligence

Adcock Ingram shareholders approve Natco Pharma acquisition scheme

October 10, 2025 at 06:00 AM UTCBy FilingReader AI

Adcock Ingram Holdings Limited shareholders have approved the scheme resolution for Natco Pharma South Africa to acquire all remaining ordinary shares not already held by Natco, Bidvest, or as treasury shares. The general meeting, held on October 9, 2025, saw 98.66% of votes cast "For" the resolution and 1.34% "Against." A total of 36,825,684 shares were voted, representing 73.16% of the total issued shares entitled to be voted.

The approval signifies a key step towards the scheme's implementation, which remains subject to the fulfillment or waiver of outstanding conditions precedent detailed in the circular dated September 9, 2025.

Upon the scheme becoming unconditional and the TRP issuing a compliance certificate, Adcock Ingram's ordinary shares will be delisted from the JSE Limited. Shareholders recorded on the scheme record date will receive a scheme consideration of R75.00 per Adcock Ingram share.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when ADCOCK INGRAM HOLDINGS LIMITED publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →